A fully Human Anti-TNFalpha Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world. AbbVie GK and Eisai Co., Ltd. today announced an approval of additional indication of HUMIRA (generic name: adalimumab [recombinant], hereafter “HUMIRA”), a fully human anti-TNFalpha monoclonal antibody, for the treatment of pyoderma gangrenosum (hereafter “PG”). HUMIRA...
